OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
April 12, 2013
April 11, 2013
Maryland is the latest state to consider whether to include additional requirements for substitution of biological products
April 10, 2013
As an important method for improving the stability of parenterals, lyophilization is fairly well understood, but can still benefit from several advancements in the technology.
With high productivity achieved, makers of cell-culture media are working to optimize product quality through better understanding and control of raw materials and production processes.
The trick to taste-masking in solid dosage forms is to never let the taste buds have a chance.
April 08, 2013
Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars.
April 02, 2013
Industry is moving toward closed-loop control of continuous processing.
Experts describe best practices for sterility assurance in parenteral drug manufacturing. This article contains bonus online-exclusive material.
Sound policies are needed to govern the substitution of interchangeable biologics.
A Q&A with Tony Hitchcock, head of manufacturing at Cobra Biologics.